Aims & Scope
Drugs promotes optimum pharmacotherapy by providing a programme of review and original research articles on the most important aspects of clinical pharmacology and therapeutics.
The Journal includes: -Leading/current opinion articles providing an overview of contentious or emerging issues. -Definitive reviews of drugs and drug classes, and their place in disease management. -Therapy in Practice articles including recommendations for specific clinical situations. -High-quality, well designed, original clinical research. -Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. -AdisInsight Reports summarising development at first global approval.
Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content.
In addition, articles published in Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
View Aims & ScopeMetrics & Ranking
Impact Factor
| Year | Value |
|---|---|
| 2025 | 14.4 |
| 2024 | 13.00 |
Journal Rank
| Year | Value |
|---|---|
| 2024 | 588 |
Journal Citation Indicator
| Year | Value |
|---|---|
| 2024 | 5488 |
SJR (SCImago Journal Rank)
| Year | Value |
|---|---|
| 2024 | 3.362 |
Quartile
| Year | Value |
|---|---|
| 2024 | Q1 |
h-index
| Year | Value |
|---|---|
| 2024 | 201 |
Impact Factor Trend
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.
Licensing & Copyright
This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.
Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Citation: 951
Authors: Shubhasree, Ann, Massimo, Sarfaraz, Daniella M.
-
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Citation: 669
Authors: James A, Steven L, Marin H
-
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
Citation: 608
Authors: Richard J.